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 2 
Abstract  23 
 24 
Urinary tract infections (UTIs) are among the most common infectious diseases of humans, 25 
with Escherichia coli responsible for >80% of all cases. Asymptomatic bacteriuria (ABU) 26 
occurs when bacteria colonize the urinary tract without causing clinical symptoms and can 27 
affect both catheterized (catheter-associated ABU or CA-ABU) and non-catheterized patients. 28 
Here, we compared the virulence properties of a collection of ABU and CA-ABU nosocomial 29 
E. coli isolates in terms of antibiotic resistance, phylogenetic grouping, specific UTI-30 
associated virulence genes, hemagglutination characteristics and biofilm formation. CA-ABU 31 
isolates were similar to ABU isolates with regards to the majority of these characteristics; 32 
exceptions were that CA-ABU isolates had a higher prevalence of the polysaccharide capsule 33 
marker genes kpsMT II and kpsMT K1 while more ABU strains were capable of mannose-34 
resistant hemagglutination. To examine biofilm growth in detail we performed a global gene 35 
expression analysis on two CA-ABU strains that formed a strong biofilm and possessed a 36 
limited adhesin repertoire. The gene expression profile of the CA-ABU strains during biofilm 37 
growth showed considerable overlap with that previously described for the prototype ABU E. 38 
coli strain 83972. This is the first global gene expression analysis of E. coli CA-ABU strains. 39 
Overall, our data suggests that nosocomial ABU and CA-ABU E. coli isolates possess similar 40 
virulence profiles. 41 
 42 
 43 
Key words: Urinary tract infection, Escherichia coli, Catheter-associated urinary tract 44 
infection, Asymptomatic bacteriuria. 45 
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 3 
Introduction 46 
 47 
Urinary tract infections (UTIs) are among the most common infectious diseases acquired in 48 
nosocomial settings. UTIs may be symptomatic (e.g. cystitis and pyelonephritis) or 49 
asymptomatic. Asymptomatic bacteriuria (ABU) is an asymptomatic carrier state that 50 
resembles commensalism. ABU patients often carry >105 CFU/ml of urine of a single 51 
bacterial strain without symptoms; in nosocomial settings ABU occurs frequently in both 52 
catheterized and non-catheterized patients. In catheterized patients, the risk of bacteriuria is 53 
estimated to be 5-10% per day (46) and most patients with an indwelling urinary catheter for 54 
thirty days or longer develop bacteriuria (35). ABU in catheterized and non-catheterized 55 
patients may also lead to symptomatic UTI with patients experiencing fever, suprapubic 56 
tenderness and in some cases bacteraemia, acute pyelonephritis and death (16, 45).  57 
 58 
ABU is caused by a range of Gram-negative and Gram-positive organisms including 59 
Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Providencia stuartii, 60 
Staphylococcus epidermidis and Enterococcus faecalis (16, 46). In many cases the bacteria 61 
that cause these infections are resistant to multiple antibiotics and thus they pose a serious 62 
threat to the safety and proper functioning of health care facilities. E. coli is one of the most 63 
common causes of nosocomial UTIs (including ABU) (17, 36). Many ABU E. coli strains are 64 
phylogenetically related to virulent uropathogenic E. coli (UPEC) strains, with differences in 65 
virulence properties being multi-factorial and associated with variable combinations of 66 
genotypic and phenotypic factors (26, 49). The prototype ABU E. coli strain 83972 is a B2 67 
clinical isolate capable of long-term bladder colonization, as shown in human inoculation 68 
studies (14, 38). Bladder infection with E. coli 83972 fails to induce a host inflammatory 69 
response and this is associated with the attenuation of several virulence determinants 70 
including type 1, P and F1C fimbriae (24, 32, 47). The lack of fimbriae appears to be 71 
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 4 
essential, as a P-fimbriated and adherent transformant of E. coli 83972 triggers inflammation 72 
in the human urinary tract (47).  73 
 74 
The characteristics of E. coli that cause asymptomatic bacteriuria in catheterized patients 75 
(catheter-associated ABU or CA-ABU) and their relationship to ABU E. coli in non-76 
catheterized patients have not been investigated. The insertion and presence of an indwelling 77 
catheter predisposes to infection by causing damage to the uroepithelial mucosa, provides a 78 
surface for biofilm formation and can affect normal functioning and voiding of the bladder (7, 79 
16). Therefore, E. coli causing asymptomatic bacteriuria in non-catheterized and catheterized 80 
patients may utilise different strategies to efficiently colonize the urinary tract. In this study 81 
we have compared the molecular characteristics, phenotypic properties and antimicrobial 82 
resistance profiles of 176 consecutively isolated ABU E. coli strains (from non-catheterized 83 
patients) and CA-ABU E. coli strains from the same geographic area. Biofilm formation was 84 
identified as a common feature for both ABU and CA-ABU strains and we explored this 85 
further by examining the transcriptome of two CA-ABU E. coli strains during biofilm growth 86 
and comparing this with the transcriptome for ABU E. coli 83972 grown under the same 87 
conditions.  88 
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 5 
Materials and Methods 89 
 90 
Patients and bacterial isolates. Eighty-eight E. coli ABU and 88 E. coli CA-ABU isolates 91 
were obtained from urine samples of patients at the Princess Alexandra Hospital (Brisbane, 92 
Australia) during the period of February to July, 2006. ABU was defined as a clean-catch 93 
voided urine specimen with counts of >105 CFU/ml of a single organism. There were no 94 
ABU patients who were catheterized. CA-ABU was defined by the presence of an indwelling 95 
catheter and a urine specimen with counts of >105 CFU/ml. ABU and CA-ABU patients had 96 
no conditions indicative of symptomatic UTI (i.e fever, suprapubic tenderness or 97 
costovertebral angle tenderness) in the 48 hour period prior to or following urine collection. 98 
ABU patients (67% female) had a mean age of 66 years (range 20-100 years); CA-ABU 99 
patients (46% female) had a mean age of 56 years (range 17-94 years). The most common co-100 
morbid conditions were: ABU (23% endocrine, 19% cardiovascular dysfunction, 16% 101 
neurological and 15% urological) and CA-ABU (51% neurological, 22% endocrine, 15% 102 
urological, 7% musculoskeletal and 7% cardiovascular dysfunction). Urine cultures were 103 
performed as part of ward screening. All E. coli isolates were identified by typical 104 
morphology, lactose fermentation and positive spot indole test. Isolates that did not meet 105 
these criteria were identified in full by VITEK 2-GN card (bioMérieux). Isolates were tested 106 
for resistance to common antimicrobial agents using VITEK 2 at the Princess Alexandra 107 
Hospital. E. coli 83972 is a prototype ABU clinical isolate originally isolated from a young 108 
Swedish girl who carried it for 3 years without adverse affects (1, 25). All strains were 109 
routinely grown at 37°C on solid or in liquid Luria-Bertani (LB) medium.  110 
 111 
PCR screening. The presence of the following virulence genes was assessed for each ABU 112 
and CA-ABU isolate: fimH (type 1 fimbriae adhesin), papGI-III (P fimbriae adhesins), flu 113 
(Antigen 43), focG (F1C fimbriae subunit protein), sfaS (S fimbriae adhesin), afa/draBC 114 
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 6 
(Afa/Dr chaperone and anchoring proteins), mrkB (type 3 fimbriae chaperone protein), hlyA 115 
(hemolysin), cnf1 (cytotoxic necrotizing factor 1), fyuA (yersiniabactin receptor), iutA 116 
(aerobactin receptor), iroN (salmochelin receptor), kpsMT II (group II capsule), kpsMT III 117 
(group III capsule), kpsMT K1 (K1 capsule), kpsMT K5 (K5 capsule). Methods for bacterial 118 
DNA preparation, primer sequences and reaction conditions have been described previously 119 
(22, 23, 29, 42). The E. coli phylogenetic group of origin was determined using a three-locus 120 
PCR-based method (4). All strains were tested in duplicate with appropriate positive and 121 
negative controls.  122 
 123 
Phenotypic assays. The capacity of bacteria to express type 1 fimbriae was assayed by their 124 
ability to agglutinate yeast cells on glass slides (34). Those strains that reacted negative in 125 
this assay were retested after three successive rounds of 48 h static growth in LB medium. 126 
Mannose-resistant hemagglutination (MRHA) was assessed as previously described (9). 127 
Hemolysin production was detected on sheep blood agar plates as previously described (21). 128 
Strains that produced a clear zone of lysis after incubation for 24 h at 37°C were considered 129 
positive. Motility was assayed by inoculating 0.25% LB agar plates with 2 µl of overnight 130 
liquid cultures, and measuring the diameter of bacterial growth 16 h after inoculation.  131 
 132 
Biofilm assays. For screening of the isolate collection, biofilm formation on polyvinyl 133 
chloride (PVC) surfaces was monitored using 96-well microtiter plates (Falcon) following 134 
growth in synthetic urine as described previously (26). Isolates were considered as positive 135 
for biofilm formation if the stained biofilm was equal to or greater than an absorbance at 595 136 
nm of 0.5. Results represent the average of three independent experiments each with four 137 
replicates per strain. Biofilm formation by E. coli M366 and MS2034 and their respective 138 
ybtS deletion mutants were assayed in the same manner. Biofilm growth on Bard BiocathTM 139 
Foley latex catheters (Bard) was assayed for 10 ABU and 10 CA-ABU strains selected as 140 
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 7 
representative strains for the different levels of biofilm growth observed on PVC microtiter 141 
plates. The strains were grown statically for 24 h at 37°C in 3 ml of pooled human urine in 142 
the presence of a catheter section (1 cm long, vertically dissected). The urine was then 143 
removed, replaced with fresh pooled human urine from the same original source and the 144 
incubation was continued as above for a further 24 h. Following this incubation, the catheter 145 
sections were removed, washed twice with PBS, transferred to 1 ml sterile PBS and the 146 
biofilm was disrupted by vigorous vortexing using a TissueLyser (Qiagen). Bacteria were 147 
enumerated using quantitative colony counts on agar to determine the amount of biofilm 148 
growth. All experiments were repeated at least twice.  149 
 150 
Microarray experiments. DNA microarrays were performed for CA-ABU E. coli strains 151 
M366 and MS2034 as previously described (11). Briefly, M366 and MS2034 were grown to 152 
mid-exponential phase in morpholinepropanesulfonic acid (MOPS) minimal medium 153 
(supplemented with 0.2% glucose) or pooled human urine, or as a biofilm in urine in 94 mm 154 
Petri dishes (Greiner Bio-One). Each combination of strain and growth condition was 155 
performed in triplicate. Samples for RNA isolation were extracted and mixed directly with 156 
two volumes of RNAprotect Bacteria Reagent (QIAGEN AG). Total RNA was isolated and 157 
on-column DNase digestion was performed using the RNeasy Mini kit and the RNase-Free 158 
DNase set (QIAGEN AG). Purified RNA (10 µg per sample) was converted to cDNA and 159 
microarray analysis was performed according to the GeneChip Expression Analysis 160 
Technical Manual 701023, revision 4 (Affymetrix Inc., Santa Clara, CA). Labelled cDNA 161 
was hybridized to GeneChip E. coli Genome 2.0 arrays (Affymetrix). Overall, 9 samples 162 
were hybridized to 9 chips for each strain with triplicates for the three growth conditions. 163 
Hybridization, washing and staining were performed as described in the GeneChip 164 
Expression Analysis Technical Manual 701023, with the microarrays scanned using a 165 
GeneChip Scanner 3000. The 18 M366 and MS2034 arrays were normalized with the E. coli 166 
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83972 arrays previously performed under the same growth conditions (11, 33). Data analysis 167 
was performed as described previously (11). For each strain fold changes were calculated for 168 
biofilm growth compared to either planktonic growth in MOPS or planktonic growth in urine. 169 
Randomly permuting the samples 200 times gave false discovery rates of 0.0-0.7% (1-22 170 
false positive genes) for the different comparisons. The microarray data has been deposited in 171 
ArrayExpress (http://www.ebi.ac.uk/arrayexpress) under accession number E-MEXP-2298. 172 
 173 
Construction of ybtS deletion mutants. Deletion mutants of the yersiniabactin synthesis 174 
gene ybtS in strains M366 and MS2034 were constructed using the  Red recombinase gene 175 
inactivation method as previously described (5). The plasmid pKD4 was used as the template 176 
with the deletion primers previously employed by Henderson et al. (12). The PCR product 177 
was transformed into M366(pKD46) and MS2034(pKD46), respectively, and mutants were 178 
selected following growth on LB agar containing kanamycin (50 µg/ml). Deletion mutants 179 
were verified by PCR with the ybtS flanking primers 5'-gcaccgccttatacaattgg and 5'-180 
gttatcggtggcgttgttg.  181 
 182 
Statistical analysis. Comparisons of prevalence data were tested using the 2 test and 183 
Fisher’s exact test with MiniTab 15 statistical software. Comparisons of median virulence 184 
scores were tested using the Mann-Whitney U test. Differences in catheter biofilm growth 185 
were tested using a Student’s t test. The level of statistical significance was set at P < 0.05. 186 
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 9 
Results 187 
 188 
Phylogenetic grouping of ABU and CA-ABU strains. Our collection comprised 88 ABU 189 
and 88 CA-ABU E. coli strains isolated from the same geographic location. The majority of 190 
the strains belonged to phylogenetic group B2 (68% versus 8% for group A, 5% for group B1 191 
and 19% for group D) (Table 1). The distribution of phylogenetic groups did not differ 192 
significantly between the ABU and CA-ABU strains (ABU strains: 8% A, 6% B1, 68% B2, 193 
18% D; CA-ABU strains: 9% A, 3% B1, 68% B2, 19% D).  194 
 195 
Resistance to antibacterial agents. We compared the antibiogram of each ABU and CA-196 
ABU E. coli strain by examining for resistance to ampicillin, ceftazidime, cephalothin, 197 
cefazolin, ciprofloxacin, ceftriaxone, cefepime, cefoxitin, gentamicin, cephalexin, 198 
meropenem, nitrofurantoin, norfloxacin, trimethoprim-sulfamethoxazole, trimethoprim, 199 
tobramycin and piperacillin-tazobactam. There was no significant difference in the number of 200 
ABU and CA-ABU strains resistant to each antibiotic (Fig. 1). The most common antibiotic 201 
resistance was to cephalothin (57% of all strains) and ampicillin (49% of all strains); 32% of 202 
strains were susceptible to all of the antibiotics tested.  203 
 204 
Distribution of virulence genes. The prevalence of 18 defined virulence marker genes in the 205 
176 ABU and CA-ABU E. coli strains was assessed by PCR (Table 1). The median number 206 
of virulence genes for the ABU and CA-ABU strains was similar; 5 and 6 respectively. The 207 
fimH gene was the most common virulence gene and was present in 98% of both ABU and 208 
CA-ABU strains. The papG gene was detected in 42% of ABU strains and 43% of CA-ABU 209 
strains. Genes for F1C fimbriae, S fimbriae and the Afa/Dr family of adhesins were present in 210 
8-23% of strains, with similar numbers observed for ABU and CA-ABU strains. The gene 211 
encoding the autotransporter adhesin Ag43 (flu) was present in 60% of all strains, with 212 
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similar distribution among ABU and CA-ABU groups. Genes encoding the UPEC toxins 213 
hemolysin (hlyA) and cytotoxic necrotizing factor 1 (cnf1) were also found in similar 214 
numbers in ABU strains (19% hlyA positive, 27% cnf1 positive) and CA-ABU strains (27% 215 
hlyA positive and 26% cnf1 positive). Several siderophore receptor-encoding genes were 216 
examined; the fyuA gene (encoding the yersiniabactin receptor) was most prevalent (78% of 217 
ABU and 83% of CA-ABU strains), while the iutA (encoding the aerobactin receptor) and 218 
iroN (encoding the salmochelin receptor) genes were present in 35-50% of ABU and CA-219 
ABU strains (differences not significant). The only statistically significant differences in 220 
prevalence were observed for the kpsMT II gene specific for group II capsule biosynthesis 221 
and the kpsMT K1 gene, which were associated more frequently with CA-ABU isolates than 222 
ABU isolates (P = 0.005 and P = 0.002, respectively). Overall, the virulence load of isolates 223 
from both ABU and CA-ABU groups was similar. The median number of virulence factors 224 
for each phylogenetic group was as follows: ABU strains: 3 virulence factors for A, 2 for B1, 225 
7 for B2, 4 for D; CA-ABU strains: 2 for A, 1 for B1, 7 for B2, 6 for D.  226 
 227 
Distribution of virulence genes amongst ampicillin and cephalothin resistant strains. 228 
Resistance to ampicillin and cephalothin was most common among E. coli strains examined 229 
in this study. There was a significant difference in the median number of virulence factors 230 
between ampicillin resistant and ampicillin susceptible CA-ABU strains (6 versus 4; P = 231 
0.017). Ampicillin resistant CA-ABU E. coli had a significantly higher prevalence of the 232 
papG, flu, iutA and kpsMT K5 virulence genes (Table 1). There was no difference in the 233 
median number of virulence factors between ampicillin resistant and ampicillin susceptible 234 
ABU strains. The comparison between cephalothin resistant ABU and CA-ABU strains 235 
revealed the opposite distribution; the median number of virulence factors for cephalothin 236 
resistant and cephalothin susceptible ABU strains was 4 versus 7 (P = 0.004) while there was 237 
no difference between cephalothin resistant and cephalothin susceptible CA-ABU strains. 238 
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Genes found more commonly in cephalothin susceptible compared to cephalothin resistant 239 
strains included papG, focG, hlyA, cnf1 and iroN.  240 
 241 
Phenotypic characterization of ABU and CA-ABU strains. Many UTI E. coli strains carry 242 
virulence genes but fail to express the associated phenotype (26). Phenotypic assays were 243 
therefore performed to assess the expression of type 1 fimbriae, P fimbriae and hemolysin 244 
(Table 1). The majority of fimH-positive ABU and CA-ABU strains agglutinated yeast cells 245 
(95% and 94%, respectively), demonstrating functional type 1 fimbrial expression. MRHA 246 
can be promoted by several different fimbrial types including P, S, G and M fimbriae as well 247 
as the Afa/Dr family of adhesins (19). A higher percentage of ABU strains showed a MRHA 248 
phenotype compared to CA-ABU strains (34% versus 15%; P = 0.003). More strains 249 
contained the papG allele than expressed the associated MRHA phenotype; 65% ABU and 250 
29% CA-ABU papG-positive strains expressed MRHA (P = 0.002). Hemolysin assays were 251 
also performed to determine if strains possessing hlyA were hemolytic. Three hlyA-positive 252 
strains were non-hemolytic, while four strains that screened negative for hlyA were hemolytic. 253 
There was no significant difference in the number of hemolytic ABU strains (20%) and CA-254 
ABU strains (18%).  255 
 256 
Biofilm formation. The ability of each ABU and CA-ABU E. coli isolate to form a biofilm 257 
was assessed using the microtiter plate biofilm assay. The CA-ABU strains displayed no 258 
significant difference in biofilm phenotype compared to ABU strains; 48% of CA-ABU and 259 
59% of ABU strains formed a biofilm (Table 1). The mean biofilm formation value was 260 
similar for the ABU and CA-ABU groups (0.58 versus 0.54, P = 0.391) (Fig. 2). To examine 261 
how these results compared with biofilm formation on a catheter surface, we selected 10 262 
ABU and 10 CA-ABU strains that encompassed the range of biofilm formation observed on 263 
PVC microtiter plates and examined their biofilm phenotype using a catheter biofilm assay. 264 
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Under these experimental conditions, all of the ABU strains formed a biofilm equivalent to 265 
that produced by the prototype ABU E. coli strain 83972 (Fig. 3). In contrast, four of the CA-266 
ABU strains showed significantly higher levels of biofilm growth on the catheter surface 267 
compared to E. coli 83972 (P < 0.05) (Fig. 3). 268 
 269 
Global gene expression of CA-ABU E. coli strains during biofilm formation. To examine 270 
the similarity between ABU and CA-ABU strains further, two CA-ABU strains (M366 and 271 
MS2034) with a limited repertoire of known adhesins and similar biofilm growth to the 272 
prototype ABU E. coli strain 83972 were selected for further analysis (Table 2, Fig. 2). We 273 
examined the global gene expression profile of E. coli M366 and MS2034 during biofilm 274 
growth in pooled human urine as well as during planktonic growth in pooled human urine 275 
and in MOPS minimal medium. We then compared this data with that previously obtained for 276 
E. coli 83972 grown under the same conditions (11, 33).  277 
 278 
Transcriptomic analysis of M366 and MS2036 revealed that there was considerable overlap 279 
in the genes up- or down-regulated during biofilm growth versus planktonic growth in urine 280 
and MOPS minimal medium compared to E. coli 83972 (Fig. 4). Comparing biofilm and 281 
planktonic growth in urine, 69% and 57% of the up-regulated genes in M366 were also up-282 
regulated in MS2034 and 83972 respectively; under the same conditions 77% and 57% of the 283 
down-regulated M366 genes were shared with MS2034 and 83972 respectively. Overall, the 284 
three strains shared 443 genes significantly up-regulated and 498 genes down-regulated 285 
during biofilm growth in urine compared to planktonic growth in urine (Tables S1 and S2). 286 
The three strains also shared 420 genes significantly up-regulated and 709 genes down-287 
regulated during biofilm growth in urine compared to planktonic growth in MOPS (Tables S3 288 
and S4). The majority of the top 50 up-regulated genes of E. coli M366 during biofilm 289 
growth compared to planktonic growth were also up-regulated in strains MS2034 and 83972. 290 
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These genes included those encoding for cold and heat shock proteins, transcriptional 291 
regulators, enzymes, putative transport proteins and iron uptake proteins (Tables S1 and S3).  292 
 293 
We also compared the gene expression profile of M366, MS2034 and 83972 according to 294 
functional group classifications (Table 3). The two CA-ABU strains had similar numbers of 295 
genes up- or down-regulated compared to ABU 83972 for most functional groups. The most 296 
up-regulated functional groups were transcription, intracellular trafficking, secretion and 297 
signal transduction mechanisms. In contrast, the most down-regulated functional groups were 298 
translation, amino acid transport and metabolism, and secondary metabolite biosynthesis, 299 
transport, and catabolism.  300 
 301 
Up-regulation of genes involved in iron uptake. We specifically examined the transcription 302 
of genes involved in iron uptake by E. coli M366 and MS2034 during biofilm growth in urine 303 
and compared this to planktonic growth in MOPS minimal medium (Fig. 5). We observed a 304 
consistent pattern of increased gene expression, with the strongest expressed genes associated 305 
with the enterobactin, SitABCD and yersiniabactin pathways (for example, 12/19 306 
yersiniabactin genes and sitA were in the top 50 up-regulated genes of M366 during biofilm 307 
formation compared to planktonic growth in MOPS, Table S3). We next compared this data 308 
with the transcription profile for E. coli 83972 grown under the same conditions. Unlike E. 309 
coli 83972, E. coli M366 and MS2034 did not express the genes encoding for aerobactin 310 
synthesis, which is consistent with our PCR typing of these strains as iutA negative. E. coli 311 
M366 was also iroN negative and we did not detect transcription of the iroBCDEN genes. 312 
However, a major difference between the M366 and MS2034 CA-ABU strains and ABU E. 313 
coli strain 83972 was the level of expression of the yersiniabactin genes. Most of the genes 314 
involved in the yersiniabactin biosynthetic pathway as well as the fyuA receptor-encoding 315 
gene were significantly up-regulated in E. coli M366 and MS2034 compared to E. coli 83972 316 
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(Fig. 5). To examine if the biosynthesis of yersiniabactin affected biofilm formation, we 317 
deleted the ybtS gene from E. coli M366 and MS2034. There was no difference in biofilm 318 
growth between wild-type and ybtS mutant strains, suggesting that while transcription of the 319 
yersiniabactin biosynthesis genes was increased, this was not an absolute requirement for 320 
biofilm growth by E. coli M366 and MS2034 under the experimental conditions employed.  321 
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Discussion 322 
 323 
In this study we compared E. coli strains that cause ABU and CA-ABU for differences in 324 
phylogenetic group, antibiotic resistance, virulence factors and phenotypic properties 325 
(including biofilm formation). We then selected two CA-ABU strains and examined their 326 
global gene expression profile during biofilm growth in urine and compared this to the 327 
prototypical ABU E. coli strain 83972. 328 
 329 
Our analysis revealed that the majority of the ABU and CA-ABU strains belonged to 330 
phylogenetic groups B2 and D. These phylogenetic groups are most commonly associated 331 
with extraintestinal pathogenic E. coli (2, 23, 30, 39). In support of this typing we also 332 
observed a widespread occurrence of virulence factors for ABU and CA-ABU strains. Of the 333 
18 UTI-associated virulence genes examined, there was a similar prevalence rate for all genes 334 
except the group II capsule specific kpsMT II gene and the K1 capsule marker gene kpsMT 335 
K1, which were more prevalent within CA-ABU strains. This difference may reflect 336 
polysaccharide production during catheter colonization and biofilm growth by CA-ABU 337 
strains. Although there was no increased expression of capsule genes during biofilm growth 338 
in vitro for CA-ABU isolates M366 and MS2034, capsule production may be increased 339 
during host infection.  340 
 341 
An interesting finding in our study was the observation that ABU and CA-ABU strains 342 
displayed very similar profiles with respect to antibiotic resistance. Resistance to ampicillin, 343 
cephalothin, trimethoprim and trimethoprim-sulfamethoxazole were most common. This is 344 
consistent with the use of these antibiotics to treat nosocomial and community-acquired UTI. 345 
Low levels of resistance to gentamicin and quinolone antibiotics reflect their restricted use in 346 
Australia. Previous studies have epidemiologically linked antimicrobial resistance in ExPEC 347 
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strains with reduced inferred virulence, often due to a decreased prevalence of phylogenetic 348 
group B2 within antimicrobial resistant strains (20, 37, 44). In our study, cephalothin resistant 349 
ABU strains had a lower median number of virulence factors and decreased prevalence of 350 
phylogenetic group B2, compared to cephalothin susceptible ABU strains. However, analysis 351 
of group B2 ABU strains independently revealed that the difference in phylogenetic grouping 352 
between resistant and susceptible strains did not account for the difference in inferred 353 
virulence (5 versus 7 median virulence factors for group B2 cephalothin resistant and 354 
susceptible strains, P = 0.016). Interestingly, resistance to ampicillin amongst CA-ABU 355 
strains followed a reverse trend with respect to the median number of virulence factors (4 356 
versus 6 for susceptible and resistant strains, respectively). Overall, the relationship between 357 
antimicrobial resistance and virulence in our isolate collection not only varied with 358 
antimicrobial agent but also with strain clinical origin. 359 
 360 
Since UTI E. coli strains may possess virulence genes but fail to express the associated 361 
phenotype several virulence related phenotypes were examined. ABU and CA-ABU E. coli 362 
differed only with regards to MRHA, possibly due to the decreased number of papG-positive 363 
CA-ABU strains capable of MRHA under the conditions tested. While P fimbriae are not 364 
associated with persistence in normal or catheterized urinary tracts, they have been shown to 365 
enhance establishment of bacteriuria by ABU strain 83972 (1, 28, 48). Type 1 fimbriae, as 366 
determined by yeast agglutination, were expressed by the majority of the ABU and CA-ABU 367 
E. coli. This fimbrial type, unlike P fimbriae, is associated with catheter colonization and 368 
persistence in the catheterized urinary tract (28, 41). Furthermore, the introduction of a 369 
plasmid containing type 1 fimbrial genes increased catheter adherence of ABU strain 83972 370 
up to 100-fold and improved its ability to prevent colonization by pathogenic E. coli (41).  371 
 372 
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CA-ABU results from the growth of bacterial biofilms on the inner surface of the urinary 373 
catheter. Although the molecular mechanisms of biofilm formation by E. coli in the 374 
catheterized urinary tract are not fully understood, surface adhesins such as type 1 fimbriae, 375 
type 3 fimbriae and curli have been shown to contribute to biofilm growth (28, 29, 41, 43). In 376 
contrast, ABU E. coli strains are often associated with poor epithelial cell adhesion properties 377 
and thus the role of biofilm growth in colonization by these strains is less clear. Despite this, 378 
we found that the ABU and CA-ABU E. coli strains examined in this study possessed similar 379 
biofilm formation properties as assessed by the PVC microtiter plate assay. Furthermore, we 380 
did not observe any significant difference with respect to the adhesin gene repertoire of ABU 381 
and CA-ABU strains. It is possible that some ABU strains form biofilms within the bladder 382 
without invoking host responses through direct attachment to mucosal cell receptors, or that 383 
biofilm growth in the urinary tract leads to reduced virulence gene expression and thus 384 
decreased interaction with the host. Indeed, we previously found several ABU strains able to 385 
adhere to bladder epithelial cells without provoking a cytokine response (26).  386 
  387 
To examine biofilm growth in more detail, we also tested a representative selection of ABU 388 
and CA-ABU strains for their ability to form a biofilm on a catheter surface in pooled human 389 
urine. All of the ABU strains formed a similar biofilm to E. coli 83972 in this assay. Among 390 
the CA-ABU strains examined, four strains displayed a significant increase in biofilm 391 
formation relative to E. coli 83972. We have previously reported that E. coli strains which 392 
cause symptomatic and asymptomatic infections display different biofilm formation 393 
phenotypes in human urine on polystyrene microtiter plates and catheter surfaces (6). The 394 
results presented here suggest that while there is some degree of congruence between these 395 
two assays, some differences are also apparent at the strain level.  396 
 397 
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We further examined biofilm formation for selected CA-ABU strains using global gene 398 
expression analysis with comparison to the prototype ABU E. coli strain 83972. The two CA-399 
ABU strains (M366 and MS2034) selected were from the same phylogenetic group as ABU 400 
83972 and also had a limited adhesin repertoire. There was significant overlap in the genes 401 
up- or down-regulated during biofilm growth compared to planktonic growth for the three E. 402 
coli strains, with 420-709 genes shared between the three strains depending on the 403 
comparison.  404 
 405 
We focussed on the transcription of genes involved in iron uptake since free iron is strictly 406 
limited in the urinary tract. Efficient iron uptake has been suggested as a mechanism by 407 
which ABU strains grow in urine and are maintained in the bladder (31, 33). One widespread 408 
method for iron acquisition is the production of siderophores, low molecular mass iron-409 
chelating compounds, and their associated membrane receptors (27). We examined the 410 
transcription of genes involved in iron uptake by CA-ABU E. coli M366 and MS2034, with 411 
comparison to ABU strain 83972. The majority of these genes were up-regulated during 412 
biofilm growth compared to planktonic growth in MOPS minimal medium for all three E. 413 
coli strains. Most notably, genes involved in the synthesis and transport of the siderophore 414 
yersiniabactin (including the receptor-encoding fyuA gene) were up-regulated up to 88 fold in 415 
strains M366 and MS2034, with smaller changes (up to 9 fold) in strain 83972. Increased 416 
expression of the yersiniabactin pathway genes has previously been shown for ABU E. coli 417 
83972 and VR50 during biofilm formation (10, 11) and for E. coli 83972 during colonization 418 
of the human urinary tract (31). Additionally the yersiniabactin receptor FyuA is required for 419 
efficient biofilm formation by strains 83972 and VR50 in urine (10). However, when the 420 
yersiniabactin synthesis gene ybtS was deleted in strains M366 and MS2034, no change in 421 
biofilm growth was observed. Although the siderophore yersiniabactin appears to be 422 
important for biofilm formation by ABU strain 83972, this was not seen in the CA-ABU 423 
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strains examined here. Of note also is the fact that E. coli 83972 is unable to express type 1, P 424 
and F1C fimbriae (24, 32). In contrast, 93% and 34% of the ABU isolates in the present study 425 
express type 1 and MRHA fimbriae, respectively. This suggests that E. coli 83972 may use a 426 
different strategy to colonize the urinary tract compared to other ABU strains.  427 
 428 
Overall, the E. coli ABU and CA-ABU isolates in our collection had similar virulence 429 
profiles. Previous studies have compared virulence properties of E. coli ABU isolates in non-430 
catheterized patients to fecal isolates and isolates from other clinical syndromes including 431 
cystitis and pyelonephritis. Urinary isolates, including ABU E. coli, typically have higher 432 
inferred virulence than fecal isolates from healthy individuals (3, 18). Pyelonephritis isolates 433 
display the most consistent differences in virulence properties compared to ABU isolates, 434 
specifically a higher prevalence of P fimbrial genes and an increased ability to cause MRHA 435 
(18, 26). There is limited research on the virulence properties of E. coli colonizing the 436 
catheterized urinary tract, despite high numbers of catheterized patients and the high risk of 437 
developing bacteriuria once catheterized. Catheter literature has also been complicated by the 438 
lack of differentiation between bacterial isolates causing catheter-associated asymptomatic 439 
bacteriuria (CA-ABU) and catheter-associated symptomatic urinary tract infection (CAUTI), 440 
with guidelines recently published to rectify this (13, 40). Comparative studies have been 441 
carried out mainly in patients with neurogenic bladders and intermittent catheterization where 442 
there were limited or no differences between E. coli causing asymptomatic and symptomatic 443 
infections (8, 15). Since the insertion and presence of an indwelling catheter substantially 444 
changes the urinary tract environment, we compared the virulence properties of E. coli 445 
isolates causing asymptomatic bacteriuria in catheterized and non-catheterized patients. An 446 
indwelling catheter predisposes to infection by introducing bacteria into the bladder, causing 447 
damage to the uroepithelial mucosa, providing a surface for biofilm formation and can also 448 
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affect normal functioning and voiding of the bladder (7, 16). Despite this, we found little 449 
difference in virulence properties between the E. coli ABU and CA-ABU isolates.  450 
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Table 1: Distribution of phylogenetic groups and virulence factors [number and %] among ABU and CA-ABU E. coli isolates. 
 All strains  Ampicillin resistance  Cephalothin resistance 
 ABU  CA-ABU P  ABU strains P  CA-ABU strains P  ABU strains P  CA-ABU strains P 
    
 Susceptible Resistant   Susceptible Resistant   Susceptible Resistant   Susceptible Resistant  
 (n = 88) (n = 88)   (n = 45) (n = 43)   (n = 44) (n = 44)   (n = 40) (n = 48)   (n = 36) (n = 52)  
Phylogenetic 
group    
 
  
             
A 7 (8) 8 (9) NS  3 (7) 4 (9) NS  3 (7) 5 (11) NS  1 (3) 6 (13) NS  4 (11) 4 (8) NS 
B1 5 (6) 3 (3) NS  3 (7) 2 (5) NS  3 (7) 0 (0) NS  2 (5) 3 (6) NS  2 (6) 1 (2) NS 
B2 60 (68) 60 (68) NS  33 (73) 27 (63) NS  28 (64) 32 (73) NS  35 (88) 25 (52) <0.001  22 (61) 38 (73) NS 
D 16 (18) 17 (19) NS  6 (13) 10 (23) NS  10 (23) 7 (16) NS  2 (5) 14 (29) 0.005  8 (22) 9 (17) NS 
Virulence gene                    
fimH 86 (98) 86 (98) NS  45 (100) 41 (95) NS  43 (98) 43 (98) NS  40 (100) 46 (96) NS  35 (97) 51 (98) NS 
papGI 3 (3) 0 (0) NS  1 (2) 2 (5) NS  0 (0) 0 (0) NS  0 (0) 3 (6) NS  0 (0) 0 (0) NS 
papGII 16 (18) 26 (30) NS  8 (18) 8 (19) NS  6 (14) 20 (45) 0.001  8 (20) 8 (17) NS  7 (19) 19 (37) NS 
papGIII 21 (24) 17 (19) NS  13 (29) 8 (19) NS  8 (18) 9 (20) NS  15 (38) 6 (13) 0.006  9 (25) 8 (15) NS 
papG (all alleles) 37 (42) 38 (43) NS  21 (47) 16 (37) NS  14 (32) 24 (55) 0.031  22 (55) 15 (31) 0.025  15 (42) 23 (44) NS 
flu 51 (58) 55 (63) NS  25 (56) 26 (60) NS  21 (48) 34 (77) 0.004  27 (68) 24 (50) NS  23 (64) 32 (62) NS 
focG 14 (16) 20 (23) NS  9 (20) 5 (12) NS  9 (20) 11 (25) NS  11 (28) 3 (6) 0.009  11 (31) 9 (17) NS 
sfaS 8 (9) 7 (8) NS  4 (9) 4 (9) NS  5 (11) 2 (5) NS  6 (15) 2 (4) NS  2 (6) 5 (10) NS 
afa/draBC 7 (8) 7 (8) NS  6 (13) 1 (2) NS  2 (5) 5 (11) NS  4 (10) 3 (6) NS  4 (11) 3 (6) NS 
mrkB 1 (1) 3 (3) NS  0 (0) 1 (2) NS  2 (5) 1 (2) NS  1 (3) 0 (0) NS  2 (6) 1 (2) NS 
hlyA 17 (19) 24 (27) NS  12 (27) 5 (12) NS  12 (27) 12 (27) NS  13 (33) 4 (8) 0.006  11 (31) 13 (25) NS 
cnf1 24 (27) 23 (26) NS  12 (27) 12 (28) NS  11 (25) 12 (27) NS  15 (38) 9 (19) 0.049  10 (28) 13 (25) NS 
fyuA 69 (78) 73 (83) NS  34 (76) 35 (81) NS  34 (77) 39 (89) NS  31 (78) 38 (79) NS  26 (72) 47 (90) 0.026 
iutA 31 (35) 43 (49) NS  10 (22) 21 (49) 0.009  13 (30) 30 (68) <0.001  15 (38) 16 (33) NS  14 (39) 29 (56) NS 
iroN 44 (50) 37 (42) NS  27 (60) 17 (40) NS  17 (39) 20 (45) NS  30 (75) 14 (29) <0.001  16 (44) 21 (40) NS 
kpsMT II 45 (51) 63 (72) 0.005  18 (40) 27 (63) 0.033  29 (66) 34 (77) NS  18 (45) 27 (56) NS  20 (56) 43 (83) 0.006 
kpsMT III 1 (1) 4 (5) NS  0 (0) 1 (2) NS  2 (5) 2 (5) NS  0 (0) 1 (2) NS  2 (6) 2 (4) NS 
kpsMT K1 11 (13) 28 (32) 0.002  7 (16) 4 (9) NS  16 (36) 12 (27) NS  5 (13) 6 (13) NS  9 (25) 19 (37) NS 
kpsMT K5 24 (27) 34 (39) NS  9 (20) 15 (35) NS  12 (27) 22 (50) 0.029  10 (25) 14 (29) NS  11 (31) 23 (44) NS 
Virulence gene 
score, median 5 6 NS 
 5 5 NS  4 6 0.017  7 4 0.004  6 6 NS 
Phenotype                    
Yeast agglut. 82 (93) 81 (92) NS  43 (96) 39 (91) NS  41 (93) 40 (91) NS  37 (93) 45 (94) NS  33 (92) 48 (92) NS 
MRHA 30 (34) 13 (15) 0.003  16 (36) 14 (33) NS  7 (16) 6 (14) NS  18 (45) 12 (25) 0.049  9 (25) 4 (8) 0.033 
Hemolysis 18 (20) 16 (18) NS  13 (29) 5 (12) 0.045  8 (18) 8 (18) NS  14 (35) 4 (8) 0.003  8 (22) 8 (15) NS 
Motility 60 (68) 63 (72) NS  30 (67) 30 (70) NS  34 (77) 29 (66) NS  25 (63) 35 (73) NS  24 (67) 39 (75) NS 
Biofilm 52 (59) 42 (48) NS  26 (58) 26 (60) NS  27 (61) 15 (34) 0.010  24 (60) 28 (58) NS  20 (56) 22 (42) NS 
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Abbreviations: ABU, asymptomatic bacteriuria; CA-ABU, catheter-associated asymptomatic bacteriuria; MRHA, mannose-resistant 
hemagglutination; yeast agglut., yeast agglutination; fimH, type 1 fimbriae adhesin; papGI-III, P fimbriae adhesins; flu, Antigen 43; focG, F1C 
fimbriae subunit protein; sfaS, S fimbriae adhesin; afa/draBC, Afa/Dr chaperone and anchoring proteins; mrkB, type 3 fimbriae chaperone 
protein; hlyA, hemolysin; cnf1, cytotoxic necrotizing factor 1; fyuA, yersiniabactin receptor; iutA, aerobactin receptor; iroN, salmochelin 
receptor; kpsMT II, group II capsule; kpsMT III, group III capsule; kpsMT K1, K1 capsule; kpsMT K5, K5 capsule. Only significant P values (P 
< 0.05) have been shown, non significant values are labelled NS. 
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Table 2: Characteristics of CA-ABU E. coli isolates selected for transcriptome analysis 
compared with ABU E. coli strain 83972.  
Characteristic M366 MS2034 83972 
Phylogenetic group B2 B2 B2 
fimH + + NF 
papGI - - - 
papGII - - - 
papGIII - - NF 
flu - - + 
focG - - NF 
sfaS - - - 
afa/draBC - - - 
Adhesins 
mrkB - - - 
hlyA - + NF Toxins 
cnf1 - + + 
fyuA + + + 
iutA - - + 
Iron-uptake 
systems 
iroN - + + 
kpsMT II + + + 
kpsMT III - - - 
kpsMT K1 + + - 
Capsular types 
kpsMT K5 - - + 
Yeast + + - Agglutination 
MRHA - - - 
Hemolysis - - - 
Biofilm formation on PVC + + + 
Motility + + - 
Antibiotic resistance CEF AMP/CEF - 
Abbreviations: NF, non-functional; MRHA, mannose-resistant hemagglutination; PVC, 
polyvinyl chloride; CEF, cephalothin; AMP, ampicillin.  
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Table 3: Numbers of significantly up- and down- regulated E. coli MG1655 genes in each 
functional group for the E. coli strains during biofilm growth in urine compared to planktonic 
growth in urine.  
Up-regulated genes in biofilm Down-regulated genes in biofilm 
M366 MS2034 83972 M366 MS2034 83972 
Functional group 
No. % No. % No. % No. % No. % No. % 
No. of 
genes 
Amino acid transport and metabolism 28 9 39 13 36 12 93 31 102 34 85 29 296 
Carbohydrate transport and metabolism 39 13 40 13 37 12 81 27 94 32 90 30 298 
Cell cycle control, mitosis, and meiosis 6 19 9 29 7 23 8 26 9 29 6 19 31 
Cell motility 4 4 7 8 14 15 4 4 4 4 3 3 91 
Cell wall/membrane biogenesis 25 13 28 14 28 14 45 23 54 27 37 19 200 
Coenzyme transport and metabolism 22 20 24 22 23 21 16 15 24 22 16 15 108 
Defense mechanisms  2 6 3 9 9 26 6 17 9 26 1 3 35 
Energy production and conversion 25 10 21 9 32 13 71 30 84 35 74 31 240 
Function unknown 45 18 52 21 65 26 50 20 61 25 43 17 247 
General function prediction only  48 18 45 17 68 25 48 18 61 23 42 16 269 
Inorganic ion transport and metabolism 24 15 32 20 40 25 22 14 34 21 18 11 160 
Intracellular trafficking and secretion 9 25 13 36 8 22 5 14 4 11 7 19 36 
Lipid transport and metabolism 12 17 12 17 11 15 12 17 18 25 17 24 71 
Nucleotide transport and metabolism 19 24 19 24 14 18 10 13 20 26 13 17 78 
Posttranslational modification, protein turnover, chaperones 19 16 25 21 31 26 22 18 31 26 19 16 119 
Replication, recombination, and repair 26 16 30 18 33 20 20 12 23 14 18 11 165 
Secondary metabolites biosynthesis, transport, and catabolism 4 7 5 9 5 9 16 30 20 37 16 30 54 
Signal transduction mechanisms  19 16 19 16 37 32 19 16 28 24 11 9 116 
Transcription 65 28 73 31 74 31 24 10 35 15 26 11 235 
Translation  40 26 48 31 26 17 20 13 22 14 55 35 156 
Not in COGs 175 16 190 18 217 20 100 9 164 15 126 12 1065 
MG1655 (Total of above genes)  656 16 734 18 815 20 692 17 901 22 723 18 4070 
Values shaded in grey indicate the functional groups with the highest percentage of differentially 
regulated genes for each E. coli strain.  
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Legends to illustrations 
 
Figure 1: Numbers of ABU and CA-ABU E. coli isolates resistant to each antibiotic included in 
the antibiotic screening. The ‘none’ category indicates isolates that were susceptible to all 
antibiotics included in this study. There were no statistically significant differences between the 
numbers of resistant isolates in the ABU and CA-ABU groups for any antibiotic. AMP 
(ampicillin), CAZ (ceftazidime), CEF (cephalothin), CFZ (cefazolin), CIP (ciprofloxacin), CRO 
(ceftriaxone), FEP (cefepime), FOX (cefoxitin), GEN (gentamicin), LEX (cephalexin), MEM 
(meropenem), NIT (nitrofurantoin), NOR (norfloxacin), SXT (trimethoprim-sulfamethoxazole), 
TMP (trimethoprim), TOB (tobramycin) and TZP (piperacillin-tazobactam). 
 
Figure 2: Biofilm formation of ABU and CA-ABU E. coli isolates in urine. Strains were grown 
in PVC microtiter plates, washed, and stained with 0.1% crystal violet. The absorbance at 595 
nm correlates to amount of biofilm formed. Results are the average of three independent 
experiments each with four replicates. Horizontal bars indicate the mean for each infection 
category. CA-ABU E. coli isolates selected for transcriptome analysis (M366 and MS2034), and 
the relative position of ABU E. coli strain 83972 are indicated.  
 
Figure 3: Biofilm formation of selected ABU and CA-ABU E. coli isolates on Foley latex 
catheters. Catheter sections were incubated with isolates in human urine and biofilm assessed via 
colony counting. Biofilm formation as CFU per 1 cm catheter section was standardised to that of 
ABU E. coli strain 83972. Results are the average of at least duplicates with error bars indicating 
SD. The four CA-ABU isolates which had significantly higher biofilm growth than ABU E. coli 
83972 are marked with an asterisk (P < 0.05). The corresponding amount of biofilm growth for 
 at UQ Library on June 14, 2010 
jcm
.asm
.org
Downloaded from
 
 33 
each strain on PVC microtiter plates is also indicated and expressed as either low (-), medium (+) 
or high (++). 
 
Figure 4: Numbers of significantly up- and down-regulated genes of E. coli strains 83972, M366 
and MS2034 during biofilm growth compared to planktonic growth in urine (A) and MOPS 
minimal medium (B).  
 
Figure 5: Fold changes in expression of iron acquisition genes of the E. coli strains 83972, 
M366 and MS2034 during biofilm growth in urine compared to planktonic growth in MOPS 
minimal medium. 
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